FY2025 EPS Estimate for Esperion Therapeutics Cut by Analyst

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research dropped their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a research note issued on Thursday, November 28th. Zacks Research analyst K. Das now forecasts that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their previous estimate of $0.09. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.25) per share.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC dropped their price objective on Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, August 13th. StockNews.com downgraded Esperion Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Wednesday, November 27th.

Esperion Therapeutics Stock Up 10.7 %

Shares of Esperion Therapeutics stock traded up $0.30 during trading hours on Monday, hitting $3.10. 13,818,604 shares of the company's stock traded hands, compared to its average volume of 6,160,124. The company has a market cap of $610.82 million, a PE ratio of -4.64 and a beta of 0.96. Esperion Therapeutics has a twelve month low of $1.35 and a twelve month high of $3.44. The stock has a 50 day simple moving average of $2.11 and a 200-day simple moving average of $2.16.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wasatch Advisors LP boosted its stake in Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company's stock valued at $38,521,000 after purchasing an additional 6,483,070 shares during the period. Vanguard Group Inc. boosted its position in shares of Esperion Therapeutics by 71.8% during the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company's stock worth $23,655,000 after buying an additional 3,688,796 shares during the period. Geode Capital Management LLC grew its holdings in Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company's stock worth $7,148,000 after buying an additional 171,609 shares in the last quarter. Marshall Wace LLP increased its position in Esperion Therapeutics by 94.2% in the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company's stock valued at $9,554,000 after acquiring an additional 2,087,635 shares during the period. Finally, State Street Corp boosted its position in Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company's stock worth $6,360,000 after acquiring an additional 99,802 shares during the period. Institutional investors and hedge funds own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.